Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Chris Lange | Jan 28, 2019 at 8:30 AM EST

Short Sellers Back Off Major Biotechs

The January 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jan 11, 2019 at 8:25 AM EST

Major Biotechs Scare Off Short Sellers

The December 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jan 3, 2019 at 4:08 PM EST

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a down day for the broad U.S. markets. After a fairly decent Wednesday, markets as a whole took…

Paul Ausick | Jan 3, 2019 at 8:50 AM EST

Bristol-Myers, Celgene to Tie a $74 Billion Knot

Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene…

Chris Lange | Dec 27, 2018 at 8:25 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The December 14 short interest data have been compared with the previous report, and short interest moves in the selected…

Lee Jackson | Dec 21, 2018 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike, NXP Semiconductors and More

The top analyst upgrades, downgrades and other research calls from Friday included Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon,…

Chris Lange | Dec 12, 2018 at 8:40 AM EST

Short Sellers Still Can’t Make Up Their Mind on Major Biotech Stocks

The November 30 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Nov 28, 2018 at 8:20 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Nov 12, 2018 at 8:50 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The October 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 25, 2018 at 8:20 AM EDT

Short Sellers Hike Their Bets in Major Biotechs

The October 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 21, 2018 at 10:15 AM EDT

Top Biotech Earnings Reports to Watch This Week

Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Aug 27, 2018 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest in most of the…

1 2 3 4 5 … 29

Celgene : CELG

All CELG Articles

Short Sellers Back Off Major Biotechs

Major Biotechs Scare Off Short Sellers

Thursday’s Biggest Winners and Losers in the S&P 500

Bristol-Myers, Celgene to Tie a $74 Billion Knot

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Analyst Upgrades and Downgrades: Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike, NXP Semiconductors and More

Short Sellers Still Can’t Make Up Their Mind on Major Biotech Stocks

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Celgene : CELG

All CELG Articles

Short Sellers Back Off Major Biotechs

Major Biotechs Scare Off Short Sellers

Thursday’s Biggest Winners and Losers in the S&P 500

Bristol-Myers, Celgene to Tie a $74 Billion Knot

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Analyst Upgrades and Downgrades: Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike, NXP Semiconductors and More

Short Sellers Still Can’t Make Up Their Mind on Major Biotech Stocks

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It